Table 1 Patient characteristics in the eligible/landmark/out-of-landmark populations
Whole eligible population (N = 1529) | Landmark population (N = 572) | Out-of-landmark population (N = 957) | |
|---|---|---|---|
Age. median (IQR) | |||
69.7 (61.0–74.5) | 68.6 (60.5–73.9) | 70.1 (61.2–74.7) | |
Gender. n (%) | |||
Male | 1172 (76.7%) | 427 (74.7) | 745 (77.8%) |
Female | 357 (23.3%) | 145 (25.3) | 212 (22.2%) |
Performance status. n (%) | |||
0–1 | 1480 (96.8%) | 557 (97.4) | 923 (96.4%) |
2 | 49 (3.2%) | 15 (2.6) | 34 (3.6%) |
Stage. n (%) | |||
IIIb | 179 (11.7%) | 72 (12.6) | 107 (11.2%) |
IV | 1350 (88.3%) | 500 (87.4) | 850 (88.8%) |
Histology. n (%) | |||
Squamous | 619 (40.5%) | 213 (37.2) | 406 (42.4%) |
Non squamous | 674 (44.1%) | 275 (48.1) | 399 (41.7%) |
Undefined | 236 (15.4%) | 84 (14.7) | 152 (15.9%) |
Chemotherapy cycles. n (%) | |||
1 | 209 (13.7%) | – | 209 (21.8%) |
2 | 147 (9.6%) | – | 147 (15.4%) |
3 | 327 (21.4%) | – | 327 (34.2%) |
4 | 108 (7.1%) | – | 108 (11.3%) |
5 | 89 (5.8%) | – | 89 (9.3%) |
6 | 649 (42.4%) | 572 (100.0) | 77 (8.0%) |